Nkarta (NASDAQ:NKTX) Price Target Lowered to $9.00 at Mizuho

Nkarta (NASDAQ:NKTX) had its price objective lowered by Mizuho from $15.00 to $9.00 in a research note released on Thursday morning, Benzinga reports. The firm currently has a buy rating on the stock.

A number of other brokerages have also issued reports on NKTX. Raymond James raised Nkarta from an outperform rating to a strong-buy rating and set a $13.00 target price on the stock in a research report on Tuesday, October 17th. HC Wainwright dropped their target price on Nkarta from $16.00 to $10.00 and set a buy rating for the company in a research report on Wednesday, October 18th. Needham & Company LLC restated a buy rating and issued a $15.00 price objective on shares of Nkarta in a report on Wednesday, October 18th. Finally, Stifel Nicolaus decreased their price target on shares of Nkarta from $18.00 to $15.00 in a research report on Friday, August 11th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Nkarta has a consensus rating of Buy and a consensus price target of $14.67.

Nkarta Stock Down 5.0 %

Shares of NKTX stock opened at $2.36 on Thursday. Nkarta has a 1-year low of $1.28 and a 1-year high of $9.91. The company has a 50-day moving average of $1.85 and a two-hundred day moving average of $2.72.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NKTX. Quantbot Technologies LP lifted its position in shares of Nkarta by 39.1% during the 1st quarter. Quantbot Technologies LP now owns 3,200 shares of the company’s stock worth $36,000 after purchasing an additional 900 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Nkarta by 5.9% during the 1st quarter. Wellington Management Group LLP now owns 27,879 shares of the company’s stock worth $317,000 after acquiring an additional 1,554 shares in the last quarter. XTX Topco Ltd increased its holdings in shares of Nkarta by 23.1% in the 1st quarter. XTX Topco Ltd now owns 12,936 shares of the company’s stock valued at $46,000 after acquiring an additional 2,424 shares during the last quarter. State Street Corp raised its position in shares of Nkarta by 1.0% during the 1st quarter. State Street Corp now owns 276,318 shares of the company’s stock worth $3,144,000 after acquiring an additional 2,806 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in Nkarta by 26.2% during the first quarter. Ameriprise Financial Inc. now owns 17,768 shares of the company’s stock worth $63,000 after purchasing an additional 3,690 shares during the last quarter. Institutional investors and hedge funds own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.